Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Biliary Tract Neoplasms: early-phase trial registry
4 of 7 indexed Biliary Tract Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Biliary Tract Neoplasms: 7 US clinical trials tracked, 4 recruiting.
Biliary Tract Neoplasms is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Udai Kammula, running 1 of these trials.
Enrollment posture brief
Registry condition biliary-tract-neoplasms
OPEN 4 | RECR 57% | LATE 1 | EARLY 5 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Biliary Tract Neoplasms lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Biliary Tract Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Biliary Tract Neoplasms is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Biliary Tract Neoplasms trials is spread across many organizations.
Udai Kammula accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Biliary Tract Neoplasms enrolment sits around 217 participants.
Median target enrolment is 217 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
Biliary Tract Neoplasms research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
NCT01950572
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT03801083
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT07146646
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
AstraZeneca
NCT03875235
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen, a wholly owned subsidiary of Pfizer
NCT04579380
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
NCT02829918
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Biliary Tract Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Biliary Tract Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Biliary Tract Neoplasms page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Biliary Tract Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Udai Kammula sponsors the most Biliary Tract Neoplasms trials on record, review their full trial history before evaluating a specific study. See Udai Kammula's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Biliary Tract Neoplasms condition card totals 7 registered trials; most-linked intervention LY3537982; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.